BeyondSpring Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 68/100
What the filing says
BeyondSpring (market cap ~$69.7M) reported Q2 2026 net loss of $1.8M (continuing operations), with cash/short-term investments declining from $12.6M (Dec 31, 2025) to $6.5M (June 30, 2026)—a 48% cash burn in 6 months. On July 1, 2026, Min Qiu became CEO, Na Li became CFO, and Dr. Jiangwen Majeti became Vice Chairman. The company presented Phase 2 data at ASCO 2026 showing 58% two-year overall survival in 47 metastatic NSCLC patients post-ICI (median OS not reached, 28.8-month median follow-up), and preclinical AACR 2026 data suggesting Plinabulin synergy with antibody-drug conjugates. Lead program DUBLIN-4 (442-patient Phase 3 confirmatory trial) remains in preparation stage with no initiation date disclosed.
Why this rating
Leadership transition + rapid cash depletion (48% in 6 months) are material for $69.7M company. Phase 2 OS data encouraging but uncontrolled, Phase 3 not yet initiated. Runway concern real; financing risk explicit in forward-looking statements.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.